Drug Trial Radar · NCT01486797
NOX-A12 in Combination With Bendamustine and Rituximab in Relapsed Chronic Lymphocytic Leukemia (CLL)
Last checked: Nov 19, 2026Latest source record: May 22, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
28
Actual
Start
Mar 2012
Primary completion
Nov 2014
Study completion Apr 2017
Sponsor
- Lead sponsor
- TME Pharma AGIndustry
- Sponsor type
- Industry
- First posted
- Dec 7, 2011
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety and efficacy of NOX A12 in combination with a background therapy of bendamustine and rituximab (BR) chemotherapy in previously treated patients with chronic lymphocytic leukemia (CLL).
Conditions
- Chronic Lymphocytic Leukemia
Interventions
NOX-A12Drug
Pilot Group (NOX-A12 single agent, and combined with BR): * 3 cohorts of 3 patients will receive treatment with NOX-A12 alone at a single dose of 1, 2 or 4 mg/kg i.v. 2 weeks before the combination treatment of NOX-A12 and BR begins.The combination of NOX-A12 and BR will follow a dose titration design beginning at 1 mg/kg NOX-A12 (cycle 1), proceeding to dose levels of 2 mg/kg (cycle 2) and 4 mg/kg (cycle 3) NOX-A12 in combination with BR. This is followed by consolidation in cycles 4-6 when NOX-A12 will be kept at the highest individually titrated dose. Expansion Group (NOX-A12 in combination with BR): * Expansion patients will not receive single agent NOX-A12, but will receive combination treatment as for the pilot group.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and tolerability of NOX A12 alone and in combination with BR.Time frame: 30 months
- Complete remission (CR) rateTime frame: 6 months
Locations
17 sites in 4 countries. Site status is shown where the registry gives one.
Medical University Innsbruck, Division of Hematology and Oncology
Innsbruck, Austria
University Hospital Salzburg, Department of Medicine III, Center of Oncology and Hematology
Salzburg, Austria
Landeskrankenhaus Steyr, Department of Internal Medicine II (Hematology and Oncology)
Steyr, Austria
Hospital Wels-Grieskrichen, Department of Internal Medicine IV (Hematology and Oncology)
Wels, Austria
Cliniques universitaires Saint-Luc
Brussels, Belgium
Institute Jules Bordet, Department of Hematology
Brussels, Belgium
University Hospital Gasthuisberg, Department of Hematology
Leuven, Belgium
Centre Hospitalier Universitaire Clémenceau, Department of Hematology
Caen, France
Hospices Civils, Department of Hematology
Lyon, France
Centre Hospitalier Universitaire de la Milétrie, Department of Hematology
Poitiers, France
University Hospital, Institute of Hematology and Oncology
Bologna, Italy
Azienda Sanitaria Locale 8, Department of Oncology
Cagliari, Italy
University Hospital San Martino, Department of Hematology and Oncology
Genova, Italy
Niguarda Ca'Granda Hospital
Milan, Italy
University Scientific Research Institute San Raffaele
Milan, Italy
University School of Medicine, Department of Hematology
Padova, Italy
University La Sapienza, Department of Cellular Biotechnologies and Hematology
Rome, Italy
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.